Century Therapeutics, Inc. Board of Directors

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Mr. Kenneth J. Dow J.D.

Mr. Kenneth J. Dow J.D.

Senior VP of General Counsel

Dr. Chad A. Cowan Ph.D.

Dr. Chad A. Cowan Ph.D.

Chief Scientific Officer

Dr. Adrienne Farid Ph.D.

Dr. Adrienne Farid Ph.D.

Chief Development Officer, CCO & Head of Early Development

Ms. Katja Buhrer

Ms. Katja Buhrer

SVP, Head of Corporate Affairs & Strategy

Dr. Nick Trede M.D., Ph.D.

Dr. Nick Trede M.D., Ph.D.

Senior VP & Head of Clinical Development

Michael Naso Ph.D.

Michael Naso Ph.D.

Senior VP of Cell Engineering

Dr. Gregory Russotti Ph.D.

Dr. Gregory Russotti Ph.D.

Chief Technology & Manufacturing Officer

Dr. Morgan Conn Ph.D.

Dr. Morgan Conn Ph.D.

Chief Financial Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.